Mutational spectrum
Comment: The following information is limited to variants of the SMN1 gene. SMN2 gene copy number varies in the normal population from 0 to 3, with~5-10% of normal individuals having no SMN2 copy. In the presence of at least one SMN1 copy, SMN2 copies do not contribute much to protein expression. Since a homozygous loss of both SMN genes is believed to result in embryonic lethality, the presence of a SMN2 deletion excludes SMA 5q based on a homozygous SMN1 loss of function mutation. Genetic variants of SMN1 include whole-gene deletions, single exon deletions, point mutations, genomic rearrangements (http://www.hgmd.cf.ac.uk/ac/index.php), see also databases for muscular dystrophy and motor neuron diseases including SMN1 mutations (http://grenada.lumc.nl/LSDB_list/lsdbs/ SMN1 and http://www.dmd.nl/nmdb2/home.php?select_db = SMN1). For polymorphisms see NCBI accession number NM_000344.3. For SNPs see http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?geneId = 6606. For frequency of genotypes in patients see 2.3.
1.6 Analytical methods PCR (restriction digest). 3 Competitive PCR, 4 real-time PCR on lightCycler 5 or TaqMan basis. 6 Microarray typing for detection of large deletions. Multiplex ligation-dependent probe amplification (MLPA). 7 Sanger sequencing of the total coding region and the exon-intron boundaries of the SMN1 gene. If an intragenic variant is detected, it is necessary to verify that the variant has occurred in SMN1 and not SMN2. This requires additional testing by a method that facilitates SMN1-specific and SMN2-specific amplification and sequence analysis, e.g., by long-range PCR protocol 8 or subcloning. 9,10
Analytical validation
All mutations identified should be confirmed by a second, independent test (PCR, quantitative PCR, sequencing and MLPA). It is recommended to confirm the segregation of the mutation in the parents. For intragenic missense mutations to be considered pathogenic, they should not be described in the literature in control alleles, should be in evolutionary conserved regions and should be predicted by applicable software to be probably pathogenic. If feasible, patient tissue might be investigated for SMN protein staining.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence) Birth prevalence among Caucasians: 1:10.000 11 1.9 If applicable, prevalence in the ethnic group of investigated person Birth prevalence is much higher in certain inbred populations.
Diagnostic setting
Predictive testing in SMA should be considered on an individual case basis only, as long as no preventive treatment is available. Children at risk should not be tested according to the European guidelines for genetic testing in minors. In addition, it has to be offered with caution, since a small proportion of subjects with homozygous SMN1 deletions/ mutations will not develop the disease. MLPA/quantitative PCR: 100% (homozygous SMN1 deletion), heterozygous SMN1 deletion MLPA/quantitative PCR plus SMN1 sequencing: 499% (compound heterozygous SMN1 deletion/mutation) Comment: Screening does not detect the extremely rare homozygous point mutations.
TEST CHARACTERISTICS

Analytical specificity (proportion of negative tests if the genotype is not present)
PCR, restriction digest: 490% MLPA/quantitative PCR: 499% for homozygous/heterozygous SMN1 (and SMN2) deletions, no information about rare point mutations SMN1 homozygous deletion exon 7 and 8: 85-90% SMN1 homozygous deletion exon 7 only: 5-10% SMN1 homozygous deletion exon 8 only: exceptionally 12 SMN1 compound heterozygous deletion exon 7/8 and subtle mutation (intragenic deletion or duplication or point mutation): 2-5% 10, 13 SMN1 homozygous subtle mutation: exceptionally, restricted to consanguineous families 14 Proportion of patients with the clinical picture of proximal SMA displaying mutations of the SMN1 gene:
The sensitivity for SMN1 deletion and sequence analysis for the detection of SMA types I-III is probably almost 100% in a clinically well-defined patient group. Those patients with the clinical picture of SMA I-III not showing SMN1 mutations (non 5q-SMA) represent other genetic and non-genetic entities. The proportion of non 5q-SMA is o2% in SMA I+II, o10% in SMA III, while only few (o10%) of SMA IV patients are caused by SMN1 mutations.
Clinical specificity (proportion of negative tests if the disease is not present)
499% for SMN1 homozygous deletion/mutation. 90-95% for SMN2 homozygous deletion.
Positive clinical predictive value
(life time risk to develop the disease if the test is positive) 499% for homozygous SMN1 deletions, compound heterozygous SMN1 deletion/subtle mutation or homozygous subtle mutations. A small fraction (o1%) of individuals with homozygous SMN1 deletion/mutation will not develop clinical features. 0% for homozygous SMN2 deletions (according to current knowledge, see 1.5)
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Index case in that family had been tested and was positive for a homozygous SMN1 deletion/mutation: 499% (for a homozygous SMN1 deletion/mutation) Index case in that family had not been tested for SMN1 deletion/ mutation:
495% for SMA I+II, 490% for SMA III, o10% for SMA IV (for a homozygous SMN1 deletion/mutation) Carrier rates are highest in Caucasian populations (1 in 47) and lowest in African Americans (1 in 72) with a pan-ethnic carrier frequency of 1 in 54. 15 The test sensitivity for heterozygous carriers does not exceed 92-97% because two or more SMN1 copies are present on about 3-8% of normal chromosomes in most populations apart from African Americans. 15 Alleles containing more than one SMN1 gene copy mask a deletion of SMN1 on the other allele. The frequency of these 2-copy SMN1 alleles varies significantly by ethnicity and is highest in African Americans (27%) and lowest (3-4%) in Caucasians. 15 The risk reduction of a quantitative carrier screening test also depends on the gene frequency in the ethnic group. Altogether all but African Americans have a carrier detection rate exceeding 90%. 15 If a parent shows two SMN1 copies in the quantitative test, further segregation tests including the grandparents are feasible to determine whether the deletion occurred as a de novo event.
New mutations in SMA occur with a frequency of 0.84% of chromosomes, 11, 16 and subtle SMN1 gene mutations have been observed in about 2-5% of patients, that is,~2% of disease alleles. 10, 13 Given the low incidence of subtle mutations in the general population, it is not advised to exclude those for carrier-risk estimation unless the family history is positive for such a mutation.
For indications of carrier testing, SMN2 copy number determination does not provide useful additional information. The SMN2 copy number indicates the total copy number for both alleles, therefore, it is not possible to determine the SMN2 phase in unaffected individuals. 17 3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member? Yes, but it is only exceptionally requested. For limitations see 1.10.
Prenatal diagnosis
(To be answered if in 1.10 'D' was marked) 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Yes. It is advised to confirm SMA carrier status in both parents before prenatal diagnosis.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
Yes, genetic testing is the gold standard for confirmation of the diagnosis and the mode of inheritance, helps to avoid unnecessary and invasive diagnostic procedures. It allows prognostic evaluations and is the prerequisite for prenatal testing, preimplantation genetic diagnosis and genetic risk estimation of relatives.
